SUSSEX CARDIAC CENTRE EP CIC

Company limited by guarantee

Company Registration Number:
12630508 (England and Wales)

Unaudited statutory accounts for the year ended 29 May 2024

Period of accounts

Start date: 30 May 2023

End date: 29 May 2024

SUSSEX CARDIAC CENTRE EP CIC

Contents of the Financial Statements

for the Period Ended 29 May 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

SUSSEX CARDIAC CENTRE EP CIC

Directors' report period ended 29 May 2024

The directors present their report with the financial statements of the company for the period ended 29 May 2024

Directors

The directors shown below have held office during the whole of the period from
30 May 2023 to 29 May 2024

Dr James William McCready
Dr John Silberbauer


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
27 February 2025

And signed on behalf of the board by:
Name: Dr John Silberbauer
Status: Director

SUSSEX CARDIAC CENTRE EP CIC

Profit And Loss Account

for the Period Ended 29 May 2024

2024 2023


£

£
Turnover: 6,480 17,281
Cost of sales: ( 3,522 ) 0
Gross profit(or loss): 2,958 17,281
Distribution costs: 0 0
Administrative expenses: ( 4,519 ) ( 22,949 )
Operating profit(or loss): (1,561) (5,668)
Profit(or loss) before tax: (1,561) (5,668)
Profit(or loss) for the financial year: (1,561) (5,668)

SUSSEX CARDIAC CENTRE EP CIC

Balance sheet

As at 29 May 2024

Notes 2024 2023


£

£
Current assets
Cash at bank and in hand: 3,982 4,223
Total current assets: 3,982 4,223
Creditors: amounts falling due within one year: 3 ( 2,640 ) ( 1,320 )
Net current assets (liabilities): 1,342 2,903
Total assets less current liabilities: 1,342 2,903
Total net assets (liabilities): 1,342 2,903
Members' funds
Profit and loss account: 1,342 2,903
Total members' funds: 1,342 2,903

The notes form part of these financial statements

SUSSEX CARDIAC CENTRE EP CIC

Balance sheet statements

For the year ending 29 May 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 27 February 2025
and signed on behalf of the board by:

Name: Dr John Silberbauer
Status: Director

The notes form part of these financial statements

SUSSEX CARDIAC CENTRE EP CIC

Notes to the Financial Statements

for the Period Ended 29 May 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

SUSSEX CARDIAC CENTRE EP CIC

Notes to the Financial Statements

for the Period Ended 29 May 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 0 2

SUSSEX CARDIAC CENTRE EP CIC

Notes to the Financial Statements

for the Period Ended 29 May 2024

3. Creditors: amounts falling due within one year note

2024 2023
£ £
Other creditors 2,640 1,320
Total 2,640 1,320

COMMUNITY INTEREST ANNUAL REPORT

SUSSEX CARDIAC CENTRE EP CIC

Company Number: 12630508 (England and Wales)

Year Ending: 29 May 2024

Company activities and impact

The objectives of the company are to carry on activities which benefit the community and in particular, patients suffering with cardiac arrhythmia. Two arrhythmia consultants were sent to the Heart Rhythm Society Congress in the USA. Further equipment was purchased to produce a high-quality audio-visual system to allow live case broadcasting of ablation procedures so that other arrhythmia specialists can learn various procedures, including atrial and ventricular ablations and novel epicardial access techniques. Use of this system along with grant awards provides the main income for the Sussex Cardiac Centre EP CIC. New equipment was bought for the purpose of undertaking high frequency autonomic ganglia stimulation for arrhythmia research for patients within Sussex.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
27 February 2025

And signed on behalf of the board by:
Name: Dr John Silberbauer
Status: Director